Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · IEX Real-Time Price · USD
4.110
+0.010 (0.24%)
May 3, 2024, 2:57 PM EDT - Market open
Fate Therapeutics Revenue
In the year 2023, Fate Therapeutics had annual revenue of $63.53M, a decrease of -34.03%. Revenue in the quarter ending December 31, 2023 was $1.68M, a -96.22% decrease year-over-year.
Revenue (ttm)
$63.53M
Revenue Growth
-34.03%
P/S Ratio
7.35
Revenue / Employee
$351,011
Employees
181
Market Cap
467.22M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
Dec 31, 2018 | 4.74M | 634.00K | 15.44% |
Dec 31, 2017 | 4.11M | -296.00K | -6.72% |
Dec 31, 2016 | 4.40M | 1.97M | 81.08% |
Dec 31, 2015 | 2.43M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 971.00K | -1.70M | -63.63% |
Dec 31, 2012 | 2.67M | 1.50M | 128.21% |
Dec 31, 2011 | 1.17M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Voyager Therapeutics | 250.01M |
Pacific Biosciences of California | 200.52M |
Travere Therapeutics | 145.24M |
Editas Medicine | 78.12M |
Theravance Biopharma | 57.42M |
FATE News
- 10 days ago - Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting - GlobeNewsWire
- 4 weeks ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 2 months ago - Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire